Cargando…

Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling

PURPOSE: The mechanism by which cancer upregulated gene 2 (CUG2) overexpression induces cancer stem cell-like phenotypes is not fully understood. Because the increased activity and expression of epidermal growth factor receptor (EGFR) kinase have been reported in A549 cancer cells overexpressing CUG...

Descripción completa

Detalles Bibliográficos
Autores principales: Yawut, Natpaphan, Kaewpiboon, Chutima, Budluang, Phatcharaporn, Cho, Il-Rae, Kaowinn, Sirichat, Koh, Sang Seok, Chung, Young-Hwa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573319/
https://www.ncbi.nlm.nih.gov/pubmed/33116878
http://dx.doi.org/10.2147/CMAR.S271109
_version_ 1783597416085192704
author Yawut, Natpaphan
Kaewpiboon, Chutima
Budluang, Phatcharaporn
Cho, Il-Rae
Kaowinn, Sirichat
Koh, Sang Seok
Chung, Young-Hwa
author_facet Yawut, Natpaphan
Kaewpiboon, Chutima
Budluang, Phatcharaporn
Cho, Il-Rae
Kaowinn, Sirichat
Koh, Sang Seok
Chung, Young-Hwa
author_sort Yawut, Natpaphan
collection PubMed
description PURPOSE: The mechanism by which cancer upregulated gene 2 (CUG2) overexpression induces cancer stem cell-like phenotypes is not fully understood. Because the increased activity and expression of epidermal growth factor receptor (EGFR) kinase have been reported in A549 cancer cells overexpressing CUG2 (A549-CUG2) compared with control cells (A549-Vec), the Sprouty2 (Spry2) protein has gained attention as the downstream molecule of EGFR signaling. Therefore, we aim to identify the role of Spry2 in CUG2-overexpressing lung cancer cells. MATERIALS AND METHODS: Spry2 expression levels were examined in A549-CUG2 and A549-Vec cells by Western blotting and qRT-PCR. Cell migration, invasion, and sphere formation were examined after Spry2 suppression and overexpression. EGFR-Stat1 and Akt-ERK protein phosphorylation levels were detected via immunoblotting. NEK2 kinase and β-catenin reporter assay were performed for downstream of Spry2 signaling. RESULTS: Although A549-CUG2 cells showed lower levels of the Spry2 protein than A549-Vec cells, no difference in levels of Spry2 transcript was observed between both cells via qRT-PCR. Furthermore, MG132 treatment enhanced the protein levels and ubiquitination of Spry2, suggesting that Spry2 protein expression can be regulated via the ubiquitin-proteasome pathway. The enforced expression of c-Cbl, known as the binding partner of Spry2, decreased the Spry2 protein levels, whereas its knockdown oppositely increased them. Epithelial–mesenchymal transition (EMT) and sphere formation were increased in A549-Vec cells during Spry2 siRNA treatment, confirming the role of Spry2 in CUG2-induced oncogenesis. Furthermore, EMT and sphere formation were determined by the Spry2 protein levels through the regulation of EGFR-Stat1 and β-catenin-NEK2-Yap1 signaling pathways. CONCLUSION: CUG2 reduces Spry2 protein levels, the negative signaling molecule of cell proliferation, via c-Cbl, possibly activating the EGFR and β-catenin signaling pathways and, in turn, contributing to the induction of cancer stem cell-like phenotypes.
format Online
Article
Text
id pubmed-7573319
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75733192020-10-27 Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling Yawut, Natpaphan Kaewpiboon, Chutima Budluang, Phatcharaporn Cho, Il-Rae Kaowinn, Sirichat Koh, Sang Seok Chung, Young-Hwa Cancer Manag Res Original Research PURPOSE: The mechanism by which cancer upregulated gene 2 (CUG2) overexpression induces cancer stem cell-like phenotypes is not fully understood. Because the increased activity and expression of epidermal growth factor receptor (EGFR) kinase have been reported in A549 cancer cells overexpressing CUG2 (A549-CUG2) compared with control cells (A549-Vec), the Sprouty2 (Spry2) protein has gained attention as the downstream molecule of EGFR signaling. Therefore, we aim to identify the role of Spry2 in CUG2-overexpressing lung cancer cells. MATERIALS AND METHODS: Spry2 expression levels were examined in A549-CUG2 and A549-Vec cells by Western blotting and qRT-PCR. Cell migration, invasion, and sphere formation were examined after Spry2 suppression and overexpression. EGFR-Stat1 and Akt-ERK protein phosphorylation levels were detected via immunoblotting. NEK2 kinase and β-catenin reporter assay were performed for downstream of Spry2 signaling. RESULTS: Although A549-CUG2 cells showed lower levels of the Spry2 protein than A549-Vec cells, no difference in levels of Spry2 transcript was observed between both cells via qRT-PCR. Furthermore, MG132 treatment enhanced the protein levels and ubiquitination of Spry2, suggesting that Spry2 protein expression can be regulated via the ubiquitin-proteasome pathway. The enforced expression of c-Cbl, known as the binding partner of Spry2, decreased the Spry2 protein levels, whereas its knockdown oppositely increased them. Epithelial–mesenchymal transition (EMT) and sphere formation were increased in A549-Vec cells during Spry2 siRNA treatment, confirming the role of Spry2 in CUG2-induced oncogenesis. Furthermore, EMT and sphere formation were determined by the Spry2 protein levels through the regulation of EGFR-Stat1 and β-catenin-NEK2-Yap1 signaling pathways. CONCLUSION: CUG2 reduces Spry2 protein levels, the negative signaling molecule of cell proliferation, via c-Cbl, possibly activating the EGFR and β-catenin signaling pathways and, in turn, contributing to the induction of cancer stem cell-like phenotypes. Dove 2020-10-15 /pmc/articles/PMC7573319/ /pubmed/33116878 http://dx.doi.org/10.2147/CMAR.S271109 Text en © 2020 Yawut et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yawut, Natpaphan
Kaewpiboon, Chutima
Budluang, Phatcharaporn
Cho, Il-Rae
Kaowinn, Sirichat
Koh, Sang Seok
Chung, Young-Hwa
Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling
title Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling
title_full Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling
title_fullStr Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling
title_full_unstemmed Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling
title_short Overexpression of Cancer Upregulated Gene 2 (CUG2) Decreases Spry2 Through c-Cbl, Leading to Activation of EGFR and β-Catenin Signaling
title_sort overexpression of cancer upregulated gene 2 (cug2) decreases spry2 through c-cbl, leading to activation of egfr and β-catenin signaling
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573319/
https://www.ncbi.nlm.nih.gov/pubmed/33116878
http://dx.doi.org/10.2147/CMAR.S271109
work_keys_str_mv AT yawutnatpaphan overexpressionofcancerupregulatedgene2cug2decreasesspry2throughccblleadingtoactivationofegfrandbcateninsignaling
AT kaewpiboonchutima overexpressionofcancerupregulatedgene2cug2decreasesspry2throughccblleadingtoactivationofegfrandbcateninsignaling
AT budluangphatcharaporn overexpressionofcancerupregulatedgene2cug2decreasesspry2throughccblleadingtoactivationofegfrandbcateninsignaling
AT choilrae overexpressionofcancerupregulatedgene2cug2decreasesspry2throughccblleadingtoactivationofegfrandbcateninsignaling
AT kaowinnsirichat overexpressionofcancerupregulatedgene2cug2decreasesspry2throughccblleadingtoactivationofegfrandbcateninsignaling
AT kohsangseok overexpressionofcancerupregulatedgene2cug2decreasesspry2throughccblleadingtoactivationofegfrandbcateninsignaling
AT chungyounghwa overexpressionofcancerupregulatedgene2cug2decreasesspry2throughccblleadingtoactivationofegfrandbcateninsignaling